Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial

Type 2 diabetes and dyslipidemia are diseases that collectively increase the risk of patients developing cardiovascular complications. Several incretin-based drugs are reported to improve lipid metabolism, and one of these medications, anagliptin, is a dipeptidyl peptidase-4 (DPP-4) inhibitor that h...

Descripción completa

Detalles Bibliográficos
Autores principales: Onoue, Takeshi, Goto, Motomitsu, Wada, Eri, Furukawa, Mariko, Okuji, Takayuki, Okada, Norio, Kobayashi, Tomoko, Iwama, Shintaro, Sugiyama, Mariko, Tsunekawa, Taku, Takagi, Hiroshi, Hagiwara, Daisuke, Ito, Yoshihiro, Morishita, Yoshiaki, Seino, Yusuke, Suga, Hidetaka, Banno, Ryoichi, Hamada, Yoji, Ando, Masahiko, Yamamori, Etsuko, Arima, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986701/
https://www.ncbi.nlm.nih.gov/pubmed/31990936
http://dx.doi.org/10.1371/journal.pone.0228004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986701/
https://www.ncbi.nlm.nih.gov/pubmed/31990936
http://dx.doi.org/10.1371/journal.pone.0228004

Ejemplares similares